Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amgen, Inc. (AMGN) vs Cassava Sciences Inc (FLNA) Price & Performance

Amgen, Inc.Trade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs Cassava Sciences Inc — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Amgen, Inc. is far larger — about 4694× Cassava Sciences Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

AMGNFLNA
Market Cap
$224.14B$47.75M
Sector
HealthHealth
52-Week High
$417.20$4.64
52-Week Low
$271.18$0.87
Enterprise Value
$267.45B-$34.93M
Dividend Yield
2.43%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA